
Opinion|Videos|November 27, 2024
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Overview
Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and enzalutamide, aiming to improve survival outcomes while addressing the disease's high metastatic burden.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
2
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
3
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
4
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
5






